Our solution:

We combine biotechnology and pharmaceutical practices to make an impact in the wellbeing of millions of people around the world.

We cover the three key initial stages of drug development: Biotechnology Pre-Clinical Studies Clinical Studies Our main focus is on chronic wound treatment.

Studying Chronic Wounds.

For the past 15 years we studied different types of wounds that take from months to years to heal, or are never cured.

  • diabetic foot
  • pressure ulcers
  • venous ulcers
  • arterial ulcers

Action Mechanism.

The majority of chronic wounds contain biofilm, a community of bacteria that secrete a slime to protect themselves from the outside environment. This makes them resistant to antiseptics and antibiotics.

Eliminating biofilm is a key part of a successful protocol of care.

Inventing a solution.

We tested different prototypes and finally developed and perfected a gel that eliminates biofilm, successfully healing chronic wounds for the first time in history.

Our gel allows the patient to apply the treatment without recurring to a healthcare facility and covers the three main therapeutical requirements, working as:

  • Anesthetic
  • Anti-pathogenic
  • Pro-healing

A promising future for chronic wounds patients.

To this day, in our exploratory clinical trials, we have treated a total of 54 patients with ulcers that were refractory to conventional treatments and that had been open for 7 months to 3 years.

Within 60 to 95 days, we achieved 100% healing in all of the cases. Our invention is now ready to heal the world.

Our results.